Oxymorphone

CYP2D6-mediated O-demethylation of oxycodone produces oxymorphone, a Schedule II semisynthetic opioid that serves as the primary active metabolite of oxycodone. Laboratory testing applications include pain management compliance monitoring where the ratio of oxycodone to oxymorphone helps assess metabolic patterns and medication adherence, drugs of abuse screening, forensic toxicology investigations, postmortem toxicology, and clinical toxicology assessments in emergency departments evaluating suspected opioid toxicity. UTAK’s Pain Management and DAU panels contain oxymorphone in lyophilized urine and whole blood matrices at multiple concentration levels, supporting both immunoassay screening and confirmation methods used in clinical and forensic laboratories. Stock and custom QC solutions can incorporate oxycodone and related opioids such as hydrocodone, hydromorphone, morphine, codeine, fentanyl, methadone, buprenorphine, and other commonly monitored analytes to address your laboratory’s comprehensive pain management and drugs of abuse testing requirements.